Related references
Note: Only part of the references are listed.Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation
Aman P. Singh et al.
AAPS JOURNAL (2020)
Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation
Chen Bai et al.
BIOCONJUGATE CHEMISTRY (2020)
Increased Tumor Penetration of Single-Domain Antibody-Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models
Ian Nessler et al.
CANCER RESEARCH (2020)
Predicting Therapeutic Antibody Delivery into Human Head and Neck Cancers
Guolan Lu et al.
CLINICAL CANCER RESEARCH (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Takashi Nakada et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2019)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
Steven Coats et al.
CLINICAL CANCER RESEARCH (2019)
First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
Prathap Kumar Mahalingaiah et al.
PHARMACOLOGY & THERAPEUTICS (2019)
A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation
Nicholas C. Yoder et al.
MOLECULAR PHARMACEUTICS (2019)
An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates
Haleh Saber et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2019)
Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models
Sai Kiran Sharma et al.
CANCER RESEARCH (2018)
Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates
Hui Zhao et al.
CANCER RESEARCH (2018)
A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs)
Michael L. Miller et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic
Joseph A. Reddy et al.
SCIENTIFIC REPORTS (2018)
Targeting MUC16 with the THIOMAB™-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: A phase I expansion study
Kathleen Moore et al.
CANCER RESEARCH (2018)
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
Kathleen N. Moore et al.
GYNECOLOGIC ONCOLOGY (2018)
Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival
Cornelius Cilliers et al.
CANCER RESEARCH (2018)
Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy
Eshita Khera et al.
MOLECULAR SYSTEMS DESIGN & ENGINEERING (2018)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates
Xiuxia Sun et al.
BIOCONJUGATE CHEMISTRY (2017)
Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy
Cornelius Cilliers et al.
AAPS JOURNAL (2016)
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
J. F. Liu et al.
ANNALS OF ONCOLOGY (2016)
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
Fu Li et al.
CANCER RESEARCH (2016)
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
Pia M. Challita-Eid et al.
CANCER RESEARCH (2016)
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
Heather Donaghy
MABS (2016)
RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
Pavel Strop et al.
MOLECULAR CANCER THERAPEUTICS (2016)
A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity
Michael L. Miller et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models1
Jose F. Ponte et al.
NEOPLASIA (2016)
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials
Joshua Seth Eaton et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2015)
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors
Olga Ab et al.
MOLECULAR CANCER THERAPEUTICS (2015)
An FDA oncology analysis of antibody-drug conjugates
Haleh Saber et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2015)
Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates
Siddharth Sukumaran et al.
PHARMACEUTICAL RESEARCH (2015)
A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody-Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer
Brendan Bender et al.
AAPS JOURNAL (2014)
Antibody- Drug Conjugates: An Emerging Concept in Cancer Therapy
Ravi V. J. Chari et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Rational Combination Therapy of Vintafolide (EC145) with Commonly Used Chemotherapeutic Drugs
Joseph A. Reddy et al.
CLINICAL CANCER RESEARCH (2014)
Multichannel Imaging to Quantify Four Classes of Pharmacokinetic Distribution in Tumors
Sumit Bhatnagar et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Differential Effects of Predosing on Tumor and Tissue Uptake of an 111In-Labeled Anti-TENB2 Antibody-Drug Conjugate
C. Andrew Boswell et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Analytical methods for physicochemical characterization of antibody drug conjugates
Aditya Wakankar et al.
MABS (2011)
Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody-Maytansinoid Conjugates
Hans K. Erickson et al.
BIOCONJUGATE CHEMISTRY (2010)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
PR Hamann et al.
BIOCONJUGATE CHEMISTRY (2002)
Share Paper
